Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback